The company - Agreement related to additional preclinical molecules with AstraZeneca (Details) € in Thousands, $ in Millions |
1 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2022
USD ($)
|
Jun. 30, 2022
EUR (€)
|
Oct. 31, 2018
USD ($)
option
|
Oct. 31, 2018
EUR (€)
option
|
Jun. 30, 2022
preclinicalMolecule
|
Dec. 31, 2025
EUR (€)
|
Dec. 31, 2024
EUR (€)
|
Dec. 31, 2023
EUR (€)
|
|
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
| Number of preclinical molecules | preclinicalMolecule | 4 | |||||||
| Revenue from collaboration and licensing agreements | € | € 2,787 | € 12,622 | € 51,901 | |||||
| Agreement related to additional preclinical molecules with AstraZeneca | ||||||||
| Disclosure of disaggregation of revenue from contracts with customers [line items] | ||||||||
| Number of exclusive options granted | option | 4 | 4 | ||||||
| Advance received | $ 20.0 | € 17,400 | ||||||
| Revenue from collaboration and licensing agreements | $ 20.0 | € 17,400 | ||||||